{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:27:45Z","timestamp":1786512465694,"version":"build-2736575974"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression or amplification, comprises a biologically heterogeneous group of tumors with aggressive clinical behavior and limited biomarker-guided treatment options. Although chemotherapy, immune-checkpoint inhibition, poly(ADP-ribose) polymerase inhibitors, and antibody\u2013drug conjugates have expanded the therapeutic landscape, durable benefit remains constrained by genomic instability, homologous recombination deficiency, phenotypic plasticity, immune\u2013stromal interactions, and treatment-driven evolution. This Perspective critically examines how complementary translational biomodels can be organized into a fit-for-purpose framework for TNBC precision oncology. Spontaneous canine mammary tumors provide naturally evolving disease in immunocompetent hosts, whereas patient- and species-derived organoids enable scalable functional perturbation and drug-response profiling. Patient-derived xenografts preserve clinically relevant tumor heterogeneity and treatment-selected states, while genetically engineered mouse models support mechanistic interrogation of defined oncogenic events\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Large-animal platforms, including the Oncopig Cancer Model, may add anatomical, procedural, and longitudinal realism; however, their application to TNBC remains emergent and requires disease-specific validation. We further propose a patient\u2013model\u2013algorithm\u2013patient reverse-translational loop in which histopathology, radiology, molecular profiles, and functional response data are integrated through computational pathology, radiomics, multi-omics factor models, and supervised multimodal learning. Robust implementation will require patient-level data partitioning, external validation, calibration, explainability, and explicit control of batch effects, domain shift, and interspecies bias. Rather than prioritizing a single experimental system, TNBC precision medicine should rely on coordinated evidence across models with distinct and complementary strengths and limitations. This integrated strategy may improve biomarker prioritization, therapeutic hypothesis testing, and selection of clinically actionable interventions.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1896728","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:38:20Z","timestamp":1786509500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From comparative oncology to AI-enabled precision medicine: translational biomodels for triple-negative breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Tiago Veiras","family":"Collares","sequence":"first","affiliation":[{"name":"Molecular and Cellular Oncology Research Group, Cancer Biotechnology Laboratory, Technological Development Center, Federal University of Pelotas","place":["Pelotas, Brazil"]},{"name":"Department of Pathology, School of Veterinary Medicine and Animal Science, University of S\u00e3o Paulo - USP","place":["S\u00e3o Paulo, Brazil"]},{"name":"INCT T-Bio2: Translational Biodiscovery and Biomodels, CNPq","place":["Fortaleza, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana K\u00f6mmling","family":"Seixas","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Oncology Research Group, Cancer Biotechnology Laboratory, Technological Development Center, Federal University of Pelotas","place":["Pelotas, Brazil"]},{"name":"INCT T-Bio2: Translational Biodiscovery and Biomodels, CNPq","place":["Fortaleza, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pessoa","sequence":"additional","affiliation":[{"name":"INCT T-Bio2: Translational Biodiscovery and Biomodels, CNPq","place":["Fortaleza, Brazil"]},{"name":"Department of Physiology and Pharmacology, Faculty of Medicine, Federal University of Cear\u00e1","place":["Fortaleza, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia Zaidan","family":"Dagli","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Veterinary Medicine and Animal Science, University of S\u00e3o Paulo - USP","place":["S\u00e3o Paulo, Brazil"]},{"name":"INCT T-Bio2: Translational Biodiscovery and Biomodels, CNPq","place":["Fortaleza, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10469-9","article-title":"Ecotypes of triple-negative breast cancer in response to chemotherapy","volume":"654","author":"Yan","year":"2026","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0392","article-title":"Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer","volume":"74","author":"Liu","year":"2014","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1038\/s41467-020-17458-0","article-title":"Cross-species oncogenic signatures of breast cancer in canine mammary tumors","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13058-023-01705-5","article-title":"Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs","volume":"25","author":"Watson","year":"2023","journal-title":"Breast Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"18051","DOI":"10.1038\/s41598-022-21706-2","article-title":"A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer","volume":"12","author":"Inglebert","year":"2022","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00337-6","article-title":"A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology","volume":"3","author":"Guillen","year":"2022","journal-title":"Nat Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2454","article-title":"Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes","volume":"17","author":"DeRose","year":"2011","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.cell.2016.08.041","article-title":"A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds","volume":"167","author":"Bruna","year":"2016","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"R76","DOI":"10.1186\/gb-2007-8-5-r76","article-title":"Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors","volume":"8","author":"Herschkowitz","year":"2007","journal-title":"Genome Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/gb-2013-14-11-r125","article-title":"Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts","volume":"14","author":"Pfefferle","year":"2013","journal-title":"Genome Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128864","article-title":"A genetic porcine model of cancer","volume":"10","author":"Schook","year":"2015","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2015.00269","article-title":"A porcine model system of BRCA1 driven breast cancer","volume":"6","author":"Donninger","year":"2015","journal-title":"Front Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.788038","article-title":"Large animal models of breast cancer","volume":"12","author":"Mondal","year":"2022","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239391","article-title":"Induction and characterization of pancreatic cancer in a transgenic pig model","volume":"15","author":"Boas","year":"2020","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-020-00682-w","article-title":"Data-efficient and weakly supervised computational pathology on whole-slide images","volume":"5","author":"Lu","year":"2021","journal-title":"Nat BioMed Eng"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1038\/s41467-022-34275-9","article-title":"Deep learning-based image analysis predicts PD-L1 status from H&E-stained histopathology images in breast cancer","volume":"13","author":"Shamai","year":"2022","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"13604","DOI":"10.1038\/s41598-023-40219-0","article-title":"Breast cancer histopathology image-based gene expression prediction using spatial transcriptomics data and deep learning","volume":"13","author":"Rahaman","year":"2023","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12880-024-01311-7","article-title":"Development and validation of peritumoral vascular and intratumoral radiomics to predict pathologic complete responses to neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"24","author":"Xie","year":"2024","journal-title":"BMC Med Imaging"},{"key":"B31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13059-020-02015-1","article-title":"MOFA+: a statistical framework for comprehensive integration of multi-modal single-cell data","volume":"21","author":"Argelaguet","year":"2020","journal-title":"Genome Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty1054","article-title":"DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays","volume":"35","author":"Singh","year":"2019","journal-title":"Bioinformatics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1717139115","article-title":"Predicting cancer outcomes from histology and genomics using convolutional networks","volume":"115","author":"Mobadersany","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12538","article-title":"It's time to reverse our thinking: the reverse translation research paradigm","volume":"11","author":"Shakhnovich","year":"2018","journal-title":"Clin Transl Sci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1896728\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:38:28Z","timestamp":1786509508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1896728\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1896728"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1896728","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1896728"}}